Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Serial Chart Review of Repatha Use in European Subjects With Hyperlipidaemia

Next Previous
Trial Profile

Observational Serial Chart Review of Repatha Use in European Subjects With Hyperlipidaemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Hyperlipidaemia; Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Acronyms HEYMANS
  • Sponsors Amgen

Most Recent Events

  • 01 Feb 2023 The study was originally designed to have up to 12 months of follow up, However following a protocol amendment in February 2018, the follow up period was extended to 30 months.
  • 01 Feb 2023 Final Results(n=1951) assessing evolocumab persistence and discontinuation over 30 months of evolocumab treatment and to evaluate at a population level the variability in LDL-C level reductions during the study period published in the Atherosclerosis
  • 29 Aug 2022 Results of analyses assessing metrics of variability at population level in LDL-C reduction over time with evolocumab treatment presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top